Health Tech Survival: How BioticsAI Beat the FDA and Red Tape

Building a tech company in the healthcare world is nothing like building a social media app. You cannot just “move fast and break things” when people’s lives are on the line. In this industry, the clocks move slower, the stakes are sky-high, and your success depends on how well you can handle a massive amount of rules. This is the exact reality Robby Bustami, the co-founder of BioticsAI, lives every day. His company is building an AI “second pair of eyes” for ultrasounds to catch fetal abnormalities that doctors might miss. It is a field where mistakes happen way too often, and Bustami recently sat down to explain how his team fought through the red tape to get where they are.

BioticsAI did not start with a billion-dollar budget. The team actually built their first working prototype for less than $100,000. For the medical device world, that is a tiny amount of money. That early version helped them win the TechCrunch Startup Battlefield back in 2023, which gave them the eyes and the credit they needed to keep going. Fast forward to January 2024, and they finally cleared the biggest hurdle of all: they gained FDA approval. This green light means they can finally put their tech into hospitals and actually start growing.

The FDA is Not a Last-Minute Task

Most founders try to build a product first and figure out the rules later. Bustami says that is a huge mistake in healthcare. From the very first day, his team built their product with the FDA in mind. They mixed their tech development, regulatory strategy, and product design into one single path. This meant they had to work very closely with doctors, collect massive amounts of data, and run strict clinical studies before they even thought about asking the government for permission.

Many people think of the FDA process as a scary “black box” where you send in paperwork and hope for the best. Bustami argues that you don’t have to fly blind. By talking to regulators early through meetings and pre-submissions, his team was able to align their study designs with what the government actually expected to see. You can never remove the risk entirely, but you can certainly make it less of a guessing game. For many investors, the only question that matters is, “What if the FDA says no?”.

Keeping the Team Fired Up

When your biggest goal is years away, it is hard to keep a team motivated. At BioticsAI, Bustami focused on building a culture where everyone stays on the same page. He made sure that even the engineers who weren’t working on the medical side understood the “wins” happening in clinical studies or new partnerships. This kept everyone feeling like they were part of the progress, even when the finish line was still miles away.

Now that they have their FDA clearance, BioticsAI is moving into a new phase. They are starting to roll their tech out into hospitals, and they plan to go beyond pregnancy scans and into other areas of reproductive health. Building in healthcare is a marathon, not a sprint. It takes a lot of patience and a willingness to live with uncertainty. But for founders like Bustami, the reward is more than just a successful business; it is the chance to build something that actually changes how we care for people.